Biomarker ID | 455 |
PMID | 19773444 |
Year | 2009 |
Biomarker | CYR61 (Angiogenic inducer 61); MASPIN (Serpin peptidase inhibitor); AGR2 (Anterior gradient 2 homologue); |
Biomarker Basis | Expression Based |
Biomolecule | Protein |
Source | Cell Lines |
Subjects | Humans |
Regulation | Downgregulated in Docetaxel- resistant PC3-Rx cells [(CYR61 Angiogenic inducer 61 (1.5 fold); MASPIN Serpin peptidase inhibitor (1.5 fold); AGR2 Anterior gradient 2 homologue (2.4 fold)]; |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | Pathways Include(SERPINB5):- TAp63 pathway,ATF2 transcription factor network,p53 activity regulation, p53 signaling pathway |
Experiment | Docetaxel-sensitive PC3 cells Vs Docetaxel- resistant PC3-Rx cells |
Type of Biomarker | Potential Predictive |
Cohort | Docetaxel-sensitive PC3 cells and Docetaxel resistant PC3-Rx cells developed by Docetaxel dose escalation were selected for this analysis |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p<0.05 |
Method Used | iTRAQ-mass spectrometry |
Clinical | Yes |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Validated on Human patient cohort |
Technical Name | CCN1, SERPINB5, AGR2 |